| 1. |
Koki Uehara, Kenro Tanoue, Kyoko Yamaguchi, Hirofumi Ohmura, Mamoru Ito, Yuzo Matsushita, Kenji Tsuchihashi, Shingo Tamura, Hozumi Shimokawa, Taichi Isobe, Yoshihiro Shibata, Hiroshi Ariyama, Risa Tanaka, Hitoshi Kusaba, Hidetaka Yamamoto, Yoshinao Oda, Koichi Akashi, Eishi Baba, Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions., Cancer immunology, immunotherapy : CII, 10.1007/s00262-023-03505-4, 2023.08, Combined immune checkpoint blockade (ICB) is effective therapy for renal cell carcinoma (RCC). However, the dynamic changes in circulating B cells induced by combined ICB have not been clarified. The present study prospectively examined 22 patients scheduled to receive ICB for unresectable or metastatic RCC between March 2018 and August 2021. Eleven patients received combined therapy with anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab), and the other 11 patients received nivolumab monotherapy. Comprehensive phenotypes of circulating immune cells obtained prior to and after ICB therapy were analyzed by flow cytometry. Although the proportion of naïve B cells among total B cells was significantly decreased, that of switched memory B cells was significantly increased after combined therapy. In responders, the proportion of B cells among peripheral blood mononuclear cells was significantly higher prior to ICB therapy, and the proportion of switched memory B cells among total B cells tended to increase after ICB therapy. Of note, the proportion of plasmablasts among total B cells was significantly increased after ICB therapy in patients who developed severe immune-related adverse events (irAEs), and the proportion of B cells among peripheral blood decreased significantly. Furthermore, in four of five patients who developed immune-related hypophysitis following combined therapy, anti-pituitary antibody was detected in the serum. These results suggested that immune-related hypophysitis was closely related to the increase in circulating plasmablasts. Collectively, this study suggests that combined ICB promotes the differentiation of B cell populations, which is associated with efficient tumor suppression and development of irAEs.. |
| 2. |
Tomoyasu Yoshihiro, Hiroshi Ariyama, Kyoko Yamaguchi, Takashi Imajima, Satoru Yamaga, Kenji Tsuchihashi, Taichi Isobe, Hitoshi Kusaba, Koichi Akashi, Eishi Baba, Inhibition of insulin-like growth factor-1 receptor enhances eribulin-induced DNA damage in colorectal cancer., Cancer science, 10.1111/cas.15558, 113, 12, 4207-4218, 2022.09, Microtubule targeting agents (MTAs) such as taxanes are broadly used for the treatment of patients with cancer. Although MTAs are not effective for treatment of colorectal cancer (CRC), preclinical studies suggest that a subset of patients with CRC, especially those with cancers harboring the BRAF mutation, could benefit from such agents. However, two MTAs, eribulin (Eri) and vinorelbine, have shown limited clinical efficacy. Here, we report that insulin-like growth factor 1 receptor (IGF-1R) signaling is involved in Eri resistance. Using CRC cell lines, we showed that Eri induces activation and subsequent translocation of IGF-1R to the nucleus. When the activation and/or nuclear translocation of IGF-1R was inhibited, Eri induced DNA damage and enhanced G2 /M arrest. In a xenograft model using the Eri-resistant SW480 cell line, the combination of Eri and the IGF-1R inhibitor linsitinib suppressed tumor growth more efficiently than either single agent. Thus, our results indicated that combination dosing with Eri and an IGF-1R inhibitor could overcome Eri resistance and offer a therapeutic opportunity in CRC.. |
| 3. |
Hitoshi Kusaba, Shohei Moriyama, Michinari Hieda, Mamoru Ito, Hirofumi Ohmura, Taichi Isobe, Kenji Tsuchihashi, Mitsuhiro Fukata, Hiroshi Ariyama, Eishi Baba, IMPROVE bleeding score predicts major bleeding in advanced gastrointestinal cancer patients with venous thromboembolism., Japanese journal of clinical oncology, 10.1093/jjco/hyac103, 52, 10, 1183-1190, 2022.10, BACKGROUND: The incidence of venous thromboembolism has been reported as 20% in cancer patients. Anticoagulation therapy is the standard treatment for venous thromboembolism. On the other hand, bleeding should be carefully managed, because advanced cancer, particularly gastrointestinal cancer, carries a high risk of bleeding. However, the optimal management for cancer-associated thromboembolism remains to be clarified. METHODS: We retrospectively examined patients with advanced gastrointestinal cancer, including gastric cancer and colorectal cancer, who were treated with chemotherapy between 2014 and 2018 for the incidence and characteristics of venous thromboembolism and bleeding. RESULTS: In total, 194 patients (120 men, 74 women) were enrolled in this study. The underlying pathology was gastric cancer in 74 cases and colorectal cancer in 120 cases. Of the 194 patients, 40 patients (20.6%) were diagnosed with venous thromboembolism and 10 patients (5.2%) were diagnosed with concomitant pulmonary thromboembolism. Conversely, bleeding was observed in 29 patients (15%). The location of bleeding was the primary tumor in 17 cases, metastatic tumor in 9 and hemorrhagic gastric ulcer in 3. Within the venous thromboembolism group (n = 40), bleeding was observed in 10 patients (25%). Multivariate analysis showed that International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) bleeding score ≥7 correlated significantly with major bleeding (P = 0.01). In patients with a low risk of bleeding, major bleeding was observed in only three patients. CONCLUSIONS: IMPROVE bleeding score may predict the risk for bleeding in gastrointestinal cancer patients with venous thromboembolism. Selecting patients with a low risk of bleeding using with IMPROVE bleeding score is expected to contribute to the safer management of anticoagulation therapy for cancer-associated thromboembolism.. |
| 4. |
Kyoko Yamaguchi, Tomoyasu Yoshihiro, Hiroshi Ariyama, Mamoru Ito, Michitaka Nakano, Yuichiro Semba, Jumpei Nogami, Kenji Tsuchihashi, Takuji Yamauchi, Shohei Ueno, Taichi Isobe, Koji Shindo, Taiki Moriyama, Kenoki Ohuchida, Masafumi Nakamura, Yoshihiro Nagao, Tetsuo Ikeda, Makoto Hashizume, Hiroyuki Konomi, Takehiro Torisu, Takanari Kitazono, Tomohiro Kanayama, Hiroyuki Tomita, Yoshinao Oda, Hitoshi Kusaba, Takahiro Maeda, Koichi Akashi, Eishi Baba, Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model., Gastric cancer, 10.1007/s10120-022-01307-8, 2022.06. |
| 5. |
Shigeo Hisamori, Junko Mukohyama, Sanjay Koul, Takanori Hayashi, Michael Evan Rothenberg, Masao Maeda, Taichi Isobe, Luis Enrique Valencia Salazar, Xin Qian, Darius Michael Johnston, Dalong Qian, Kaiqin Lao, Naoya Asai, Yoshihiro Kakeji, Vincenzo Alessandro Gennarino, Debashis Sahoo, Piero Dalerba, Yohei Shimono, Upregulation of BMI1-suppressor miRNAs (miR-200c, miR-203) during terminal differentiation of colon epithelial cells., Journal of gastroenterology, 10.1007/s00535-022-01865-9, 2022.03. |
| 6. |
Mamoru Ito, Michitaka Nakano, Hiroshi Ariyama, Kyoko Yamaguchi, Risa Tanaka, Yuichiro Semba, Takeshi Sugio, Kohta Miyawaki, Yoshikane Kikushige, Shinichi Mizuno, Taichi Isobe, Kenro Tanoue, Ryosuke Taguchi, Shohei Ueno, Takahito Kawano, Masaharu Murata, Eishi Baba, Koichi Akashi, Macrophages are primed to transdifferentiate into fibroblasts in malignant ascites and pleural effusions., Cancer letters, 10.1016/j.canlet.2022.215597, 532, 215597-215597, 2022.02. |
| 7. |
Eijiro Shimada, Makoto Endo, Yoshihiro Matsumoto, Kenji Tsuchihashi, Mamoru Ito, Hitoshi Kusaba, Akira Nabeshima, Tomoya Nawata, Akira Maekawa, Tomoya Matsunobu, Nokitaka Setsu, Toshifumi Fujiwara, Keiichiro Iida, Makoto Nakagawa, Takeshi Hirose, Masaya Kanahori, Ryunosuke Oyama, Taichi Isobe, Hiroshi Ariyama, Kenichi Kohashi, Hidetaka Yamamoto, Yoshinao Oda, Yukihide Iwamoto, Koichi Akashi, Eishi Baba, Yasuharu Nakashima, Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?, Journal of clinical medicine, 10.3390/jcm10214972, 10, 21, 2021.10. |
| 8. |
Kenji Tsuchihashi, Hitoshi Kusaba, Tomoyasu Yoshihiro, Toshifumi Fujiwara, Nokitaka Setsu, Makoto Endo, Yoshihiro Matsumoto, Takashi Imajima, Yudai Shinohara, Mamoru Ito, Satoru Yamaga, Kenro Tanoue, Kohei Arimizu, Hirofumi Ohmura, Fumiyasu Hanamura, Kyoko Yamaguchi, Taichi Isobe, Hiroshi Ariyama, Yasuharu Nakashima, Koichi Akashi, Eishi Baba, Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin, Scientific Reports, 10.1038/s41598-020-77898-y, 10, 1, 2020.12. |
| 9. |
Nicholas Schaum, Benoit Lehallier, Oliver Hahn, Róbert Pálovics, Shayan Hosseinzadeh, Song E. Lee, Rene Sit, Davis P. Lee, Patricia Morán Losada, Macy E. Zardeneta, Tobias Fehlmann, James T. Webber, Aaron McGeever, Kruti Calcuttawala, Hui Zhang, Daniela Berdnik, Vidhu Mathur, Weilun Tan, Alexander Zee, Michelle Tan, Tabula Muris Consortium, Angela Oliveira Pisco, Jim Karkanias, Norma F. Neff, Andreas Keller, Spyros Darmanis, Stephen R. Quake, Tony Wyss-Coray, Ageing hallmarks exhibit organ-specific temporal signatures, Nature, 10.1038/s41586-020-2499-y, 583, 7817, 596-602, 2020.07. |
| 10. |
Tabula Muris Consortium, A single-cell transcriptomic atlas characterizes ageing tissues in the mouse, Nature, 10.1038/s41586-020-2496-1, 583, 7817, 590-595, 2020.07. |
| 11. |
Junko Mukohyama, Taichi Isobe, Qingjiang Hu, Takanori Hayashi, Takashi Watanabe, Masao Maeda, Hisano Yanagi, Xin Qian, Kimihiro Yamashita, Hironobu Minami, Koshi Mimori, Debashis Sahoo, Yoshihiro Kakeji, Akira Suzuki, Piero Dalerba, Yohei Shimono, miR-221 Targets QKI to Enhance the Tumorigenic Capacity of Human Colorectal Cancer Stem Cells., Cancer research, 10.1158/0008-5472.CAN-18-3544, 79, 20, 5151-5158, 2019.10. |
| 12. |
Tabula Muris Consortium, Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris., Nature, 10.1038/s41586-018-0590-4, 562, 367-372, 2018.10. |
| 13. |
Tamura S, Isobe T, Ariyama H, Nakano M, Kikushige Y, Takaishi S, Kusaba H, Takenaka K, Ueki T, Nakamura M, Akashi K, Baba E, E‑cadherin regulates proliferation of colorectal cancer stem cells through NANOG., Oncology reports, 10.3892/or.2018.6464, 40, 2, 693-703, 2018.08. |
| 14. |
Organoid Culture of Human Cancer Stem Cells.. |
| 15. |
Kenta Nio, Shuji Arita, Taichi Isobe, Hitoshi Kusaba, Kenichi Kohashi, Tatsuhiro Kajitani, Shingo Tamura, Gen Hirano, Kenji Mitsugi, Akitaka Makiyama, Taito Esaki, Hiroshi Ariyama, Yoshinao Oda, Koichi Akashi, Eishi Baba, Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 10.1007/s00280-015-2706-y, 75, 4, 829-835, 2015.04. |
| 16. |
Taichi Isobe, Shigeo Hisamori, Daniel J. Hogan, Maider Zabala, David G. Hendrickson, Piero Dalerba, Shang Cai, Ferenc Scheeren, Angera H. Kuo, Shaheen S. Sikandar, Jessica S. Lam, Dalong Qian, Frederick M. Dirbas, George Somlo, Kaiqin Lao, Patrick O. Brown, Michael F. Clarke, Yohei Shimono, miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway, ELIFE, 10.7554/eLife.01977, 3, 2014.11. |
| 17. |
Taichi Isobe, Keita Uchino, Chinatsu Makiyama, Hiroshi Ariyama, Shuji Arita, Shingo Tamura, Masato Komoda, Hitoshi Kusaba, Tsuyoshi Shirakawa, Taito Esaki, Kenji Mitsugi, Shigeo Takaishi, Koichi Akashi, Eishi Baba, Analysis of Adverse Events of Bevacizumab-containing Systemic Chemotherapy for Metastatic Colorectal Cancer in Japan, ANTICANCER RESEARCH, 34, 4, 2035-2040, 2014.04. |
| 18. |
Keita Uchino, Gen Hirano, Minako Hirahashi, Taichi Isobe, Tsuyoshi Shirakawa, Hitoshi Kusaba, Eishi Baba, Masazumi Tsuneyoshi, Koichi Akashi, Human Nanog pseudogene8 promotes the proliferation of gastrointestinal cancer cells, EXPERIMENTAL CELL RESEARCH, 10.1016/j.yexcr.2012.04.011, 318, 15, 1799-1807, 2012.09. |
| 19. |
Hozumi Kumagai, Kenta Nio, Tsuyoshi Shirakawa, Keita Uchino, Hitoshi Kusaba, Taichi Isobe, Masato Komoda, Shingo Tamura, Ryo Maeyama, Eishi Nagai, Koichi Akashi, Eishi Baba, Improvement of quality of life and survival using self-expandable metal stent placement for severe malignant stenosis of the gastric body: A case report, Journal of Medical Case Reports, 10.1186/1752-1947-6-315, 6, 1, 315, 2012.09. |
| 20. |
Taichi Isobe, Eishi Baba, Shuji Arita, Masato Komoda, Shingo Tamura, Tsuyoshi Shirakawa, Hiroshi Ariyama, Shigeo Takaishi, Hitoshi Kusaba, Takashi Ueki, Koichi Akashi, Human STEAP3 maintains tumor growth under hypoferric condition, EXPERIMENTAL CELL RESEARCH, 10.1016/j.yexcr.2011.07.022, 317, 18, 2582-2591, 2011.11. |
| 21. |
Yoshihiro Shibata, Eishi Baba, Hiroshi Ariyama, Shuji Arita, Taichi Isobe, Hitoshi Kusaba, Kenji Mitsugi, Shuji Nakano, Koichi Akashi, Irinotecan-based combination chemotherapy for metastatic small intestinal adenocarcinoma, ONCOLOGY LETTERS, 10.3892/ol_00000074, 1, 3, 423-426, 2010.05. |
| 22. |
Isobe T, Yanai S, Kusaba H, Yada S, Kuroda Y, Tamiya S, Matsumoto T, Baba E, Harada M, Effective monotherapy with amrubicin for a refractory extrapulmonary small-cell carcinoma of the liver., Case reports in medicine, 10.1155/2009/538081, 2009, 538081, 2009.06. |
| 23. |
Akitaka Makiyama, Baoli Qin, Keita Uchino, Yoshihiro Shibata, Shuji Arita, Taichi Isobe, Gen Hirano, Hitoshi Kusaba, Eishi Baba, Koichi Akashi, Shuji Nakano, Schedule-dependent synergistic interaction between gemcitabine and oxaliplatin in human gallbladder adenocarcinoma cell lines, ANTI-CANCER DRUGS, 10.1097/CAD.0b013e3283218080, 20, 2, 123-130, 2009.02. |
| 24. |
Shuji Arita, Eishi Baba, Yoshihiro Shibata, Hiroaki Niiro, Shinji Shimoda, Taichi Isobe, Hitoshi Kusaba, Shuji Nakano, Mine Harada, B cell activation regulates exosomal HLA production, EUROPEAN JOURNAL OF IMMUNOLOGY, 10.1002/eji.200737694, 38, 5, 1423-1434, 2008.05. |
| 25. |
T Isobe, TE Tanimoto, G Nakaji, T Miyamoto, S Yamasaki, K Takase, A Numata, T Fukuda, K Nagafuji, S Inaba, M Harada, Autoimmune thrombocytopenia with clonal expansion of CD8-positive T cells after autologous peripheral blood stem cell transplantation for diffuse large B-cell lymphoma, BONE MARROW TRANSPLANTATION, 10.1038/sj.bmt.1704750, 35, 3, 315-316, 2005.02. |
